Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
-
Published:2022-06
Issue:6
Volume:54
Page:850-860
-
ISSN:1061-4036
-
Container-title:Nature Genetics
-
language:en
-
Short-container-title:Nat Genet
Author:
Lips Esther H.ORCID, Kumar TapsiORCID, Megalios AnargyrosORCID, Visser Lindy L.ORCID, Sheinman Michael, Fortunato Angelo, Shah Vandna, Hoogstraat MarlousORCID, Sei Emi, Mallo DiegoORCID, Roman-Escorza MariaORCID, Ahmed Ahmed A.ORCID, Xu Mingchu, van den Belt-Dusebout Alexandra W., Brugman Wim, Casasent Anna K., Clements KarenORCID, Davies Helen R., Fu Liping, Grigoriadis AnitaORCID, Hardman Timothy M., King Lorraine M., Krete Marielle, Kristel Petra, de Maaker Michiel, Maley Carlo C.ORCID, Marks Jeffrey R., Menegaz Brian A.ORCID, Mulder Lennart, Nieboer Frank, Nowinski Salpie, Pinder SarahORCID, Quist Jelmar, Salinas-Souza Carolina, Schaapveld Michael, Schmidt Marjanka K., Shaaban Abeer M.ORCID, Shami Rana, Sridharan Mathini, Zhang John, Stobart Hilary, Collyar DeborahORCID, Nik-Zainal SerenaORCID, Wessels Lodewyk F. A.ORCID, Hwang E. Shelley, Navin Nicholas E.ORCID, Futreal P. AndrewORCID, Futreal P. Andrew, Hwang E. Shelley, Jonkers Jos, Jacco , Behbod Fariba, Rea Daniel, Bhattacharjee Proteeti, Pinto Donna, Verschuur Ellen, van Oirsouw Marja, Thompson Alastair M., Wesseling JelleORCID, Sawyer Elinor J.ORCID,
Abstract
AbstractDuctal carcinoma in situ (DCIS) is the most common form of preinvasive breast cancer and, despite treatment, a small fraction (5–10%) of DCIS patients develop subsequent invasive disease. A fundamental biologic question is whether the invasive disease arises from tumor cells in the initial DCIS or represents new unrelated disease. To address this question, we performed genomic analyses on the initial DCIS lesion and paired invasive recurrent tumors in 95 patients together with single-cell DNA sequencing in a subset of cases. Our data show that in 75% of cases the invasive recurrence was clonally related to the initial DCIS, suggesting that tumor cells were not eliminated during the initial treatment. Surprisingly, however, 18% were clonally unrelated to the DCIS, representing new independent lineages and 7% of cases were ambiguous. This knowledge is essential for accurate risk evaluation of DCIS, treatment de-escalation strategies and the identification of predictive biomarkers.
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Kerlikowske, K. Epidemiology of ductal carcinoma in situ. J. Natl Cancer Inst. Monogr. 41, 139–141 (2010). 2. Ryser, M. D. et al. Cancer outcomes in DCIS patients without locoregional treatment. J. Natl Cancer Inst. 111, 952–960 (2019). 3. Maxwell, A. J. et al. Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ. Eur. J. Surg. Oncol. 44, 429–435 (2018). 4. Shaaban, A. M. et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. Br. J. Cancer 124, 1009–1017 (2021). 5. Hwang, E. S. et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 9, e026797 (2019).
Cited by
48 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|